From: Innovation, Science and Economic Development Canada
COVID-19 Joint Biomanufacturing Subcommittee Meeting: June 23, 2020
Proposal Considered: Fill and Finish and Bill of Materials
Name of Members: | Nature of Interest | Action Taken |
---|---|---|
|
M. Lievonen was previously employed by Sanofi Pasteur (past president, retired in 2016) and holds modest shares (current value of approximately $500). He is no longer active with the company. | As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary. |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
R. Brunham has an application submitted for funding under the COVID-19 Strategic Innovation Fund – this application does not relate to biomanufacturing. | As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary. |
|
C. Procyshyn is the co-founder and CEO of Vanrx, a company that produces biomanufacturing machinery | Deemed a conflict of interest, C. Procyshyn recused himself from the deliberations and recommendations. |
|
None | N/A |
COVID-19 Joint Biomanufacturing Subcommittee Meeting: June 25th; July 6, 2020
Proposal Considered: National Research Council – Royalmount (announced – August 31)
Name of Members: | Nature of Interest | Action Taken |
---|---|---|
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
Did not attend the meeting. | N/A |
|
None | N/A |
|
C. Procyshyn is the co-founder and CEO of Vanrx, a company that produces biomanufacturing machinery. Prior to the creation of the task force, NRC had purchased a Vanrx machine. The CVTF played no role in the advice on the purchase of the machine. | As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary. |
|
None | N/A |
COVID-19 Joint Biomanufacturing Subcommittee Meeting: July 6, 2020 (with follow-up discussion on July 10, 2020)
Precision NanoSystems (Biomanufacturing Project Announced February 2nd)
Name of Members: | Nature of Interest | Action Taken |
---|---|---|
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
N. Harrison interacts regularly with Precision NanoSystems. | Deemed a conflict of interest, N. Harrison recused herself from deliberations and recommendations. |
|
Dalhousie University, where J. Langley is employed, may be considered as a potential study site for Precision NanoSystems' clinical trials; however, no contractual relationship is currently in place. Research funds for these trials would be paid to Dalhousie University. | As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary. |
|
C. Procyshyn is the co-founder and CEO of Vanrx, a company that produces biomanufacturing machinery. Precision NanoSystems indicated that Vanrx is a potential contributor towards establishing manufacturing infrastructure, perhaps through the purchase of a Vanrx machine. | Deemed a conflict of interest, C. Procyshyn recused himself from deliberations and recommendations. |
|
None | N/A |
|
Precision NanoSystems indicated that several Canadian companies could use its platform, including a company in which L. Tyrrell has an interest. | As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary. |
|
None | N/A |
|
None | N/A |
COVID-19 Joint Biomanufacturing Subcommittee Meeting: July 6, 2020 (with follow-up discussion on July 14, 2020)
Proposal Considered: KABS Laboratories (Announced March 16, 2021)
Name of Members: | Nature of Interest | Action Taken |
---|---|---|
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
COVID-19 Joint Biomanufacturing Subcommittee Meeting: July 6, 2020 (with follow-up discussion on July 14, 2020)
Proposal Considered: Novocol Pharma (Announced March 16, 2021)
Name of Member: | Nature of Interest | Action Taken |
---|---|---|
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
C. Procyshyn is the co-founder and CEO of Vanrx, a company that produces biomanufacturing machinery. Novocol Pharma indicated that it was considering making a purchase from Vanrx. | Deemed a conflict of interest, C. Procyshyn recused himself from discussion, deliberations and recommendations. |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
COVID-19 Joint Biomanufacturing Subcommittee Meeting: June 29, 2020 (with follow-up discussion on September 4, 2020)
Proposal Considered: Sanofi (Announced March 31, 2021)
Name of Member: | Nature of Interest | Action Taken |
---|---|---|
|
M. Lievonen was previously employed by Sanofi Pasteur (past president, retired in 2016) and holds modest shares (current value of approximately $500). He is no longer active with the company. | Not considered a direct, material conflict but, in an abundance of caution, M. Lievonen recused himself from the meeting on September 4, at which recommendations were made. |
|
None *Was not a member of the JBS on June 29. *Was not in attendance at the meeting on September 4. |
N/A |
|
None *Was not in attendance at the meeting on September 4. |
N/A |
|
None | N/A |
|
M. De Wilde was employed by Sanofi Pasteur in 2013, but holds no shares. *Was not a member of the JBS on June 29. |
Not considered a direct, material conflict but, in an abundance of caution, M. De Wilde recused himself from the meeting on September 4, at which recommendations were made. |
|
None *Was not in attendance at the meeting on September 4. |
N/A |
|
Dalhousie University, where J. Langley is employed, has collaborated with Sanofi Pasteur in the past on clinical trials. There is a challenge unit named after Sanofi Pasteur. She has no personal financial interests in the arrangement. J. Langley has collaborated on research projects outside of clinical trials with scientists from Sanofi (no financial compensation). J. Langley served as a consultant to Sanofi on influenza vaccines in 2018 (this was an ad hoc advisory board). Payment for this work was directed to academic activity in Dalhousie University's Department of Pediatrics. |
As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary. |
|
None *Was not in attendance at the meeting on September 4. |
N/A |
|
B. Rovinski worked for Sanofi over 20 years ago. | Not considered a direct, material conflict but, in an abundance of caution, B. Rovinski recused himself from the meeting on September 4, at which recommendations were made. |
|
None *Was not a member of the JBS on June 29. *Was not in attendance at the meeting on September 4. |
N/A |
|
S. van den Hurk held a small contract with Sanofi Pasteur regarding preclinical studies 10 years ago. *Was not a member of the JBS on June 29. |
As there are not direct, material linkages, it was not considered a conflict and recusal was not deemed necessary. |
|
None *Was not a member of the JBS on June 29. |
N/A |
COVID-19 Joint Biomanufacturing Subcommittee Meeting: January 21, 2021
Proposal Considered: Resilience Biotechnologies Inc. (Announced May 18, 2021)
Name of Member: | Nature of Interest | Action Taken |
---|---|---|
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
Resilience Biotechnologies Inc. indicated that it has had discussions with a number of vaccine developers related to their COVID-19 vaccine candidates. | Not considered a direct, material conflict but, in an abundance of caution, M. De Wilde recused himself from deliberations and recommendations. |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
None | N/A |
|
Resilience Biotechnologies Inc. indicated that it has had discussions with a number of vaccine developers related to their COVID-19 vaccine candidates. | Not considered a direct, material conflict but, in an abundance of caution, S. van den Hurk recused herself from deliberations and recommendations. |
|
None | N/A |